Amryt Pharma plc (AMYT)
Price:
14.70 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Intra-Cellular Therapies, Inc.
VALUE SCORE:
0
2nd position
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
10
The best
Lantheus Holdings, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
NEWS
Poolbeg Pharma beefs up leadership; brings key players from succesful Amryt Pharma team
proactiveinvestors.com
2023-11-09 02:50:45In a strategic move to strengthen its management team, Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced the appointment of key former executives from Amryt Pharma, underscoring its commitment to advancing its clinical assets. Chairman Cathal Friel, who co-founded both Poolbeg and Amryt, will spearhead a similar strategic approach followed by Amryt, which successfully developed drugs for unmet medical and bought in commercial assets before being sold for just shy of $1.5bn.
Amryt Pharma: Final Chance To Pick Up An Attractive CVR
seekingalpha.com
2023-04-11 07:56:33Amryt Pharma is being acquired at $14.50 per share and a contingent value right and is trading at $14.69. The contingent value right consists of 2 milestones that pay out $1 and $1.50 on certain conditions.
Why Shares of Amryt Pharma Jumped This Week
fool.com
2023-01-12 15:32:07A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares.
Acquisition Of Amryt Pharma: How To Profit From Orphan Drugs Developers
seekingalpha.com
2023-01-12 13:52:52Amryt Pharma plc will be acquired by Chiesi Farmaceutici S.p.A. Amryt Pharma is valued at $1.25 billion plus $225 million upon achievement of certain pipeline development milestones.
New Strong Sell Stocks for December 7th
zacks.com
2022-12-07 08:17:06ABST, AMYT and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on December 7, 2022.
New Strong Sell Stocks for November 17th
zacks.com
2022-11-17 09:02:17BRFS, AOS and AMYT have been added to the Zacks Rank #5 (Strong Sell) List on November 17, 2022.
New Strong Sell Stocks for November 16th
zacks.com
2022-11-16 09:02:12EGO, BRFS and AMYT have been added to the Zacks Rank #5 (Strong Sell) List on November 16, 2022.
New Strong Sell Stocks for November 10th
zacks.com
2022-11-10 09:02:20AMYT, CHRD and BKI have been added to the Zacks Rank #5 (Strong Sell) List on November 10, 2022.
Amryt Pharma PLC (AMYT) Q3 2022 Earnings Call Transcript
seekingalpha.com
2022-11-05 22:34:22Amryt Pharma PLC (NASDAQ:AMYT ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - CEO & Director Rory Nealon - CFO, COO & Company Secretary Sheila Frame - President, Americas Tracy Cunningham - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Edward Nash - Canaccord Genuity Catherine Novack - Jones Research Brian White - Shore Capital Group Douglas Tsao - H.C. Wainwright & Co. Operator Good morning, and welcome to the Amryt Pharma Q3 2022 Results Call and Webcast.
Amryt to Report Q3 2022 Results on November 3, 2022
globenewswire.com
2022-10-19 07:00:00A mryt to Report Q 3 202 2 Results on November 3 , 2022
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022
globenewswire.com
2022-09-07 07:00:00Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022
Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-08-06 04:40:10Amryt Pharma plc (NASDAQ:AMYT ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - Chief Executive Officer Rory Nealon - Chief Financial Officer and Chief Operating Officer Jordi Casals - President of EMEA Region Sheila Frame - President of Americas Tracy Cunningham - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Catherine Novack - Jones Research Douglas Tsao - H.C. Wainwright & Co. Max Herrmann - Stifel, Nicolaus & Company, Inc. Brian White - Shore Capital Stockbrokers Ltd.
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2022-08-04 12:02:19Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amryt to Report Q2 2022 Results on August 4, 2022
globenewswire.com
2022-07-21 07:00:00DUBLIN, Ireland, and Boston MA, July 21 , 202 2 , Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the second quarter 2022 will be released on Thursday , August 4 , 202 2 at 0700 E T/1200 BST.
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
zacks.com
2022-07-14 13:10:29The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.
Amryt Pharma PLC Sponsored ADR (AMYT) Surges 7.5%: Is This an Indication of Further Gains?
zacks.com
2022-06-24 10:09:33Amryt Pharma PLC Sponsored ADR (AMYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
No data to display
Poolbeg Pharma beefs up leadership; brings key players from succesful Amryt Pharma team
proactiveinvestors.com
2023-11-09 02:50:45In a strategic move to strengthen its management team, Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced the appointment of key former executives from Amryt Pharma, underscoring its commitment to advancing its clinical assets. Chairman Cathal Friel, who co-founded both Poolbeg and Amryt, will spearhead a similar strategic approach followed by Amryt, which successfully developed drugs for unmet medical and bought in commercial assets before being sold for just shy of $1.5bn.
Amryt Pharma: Final Chance To Pick Up An Attractive CVR
seekingalpha.com
2023-04-11 07:56:33Amryt Pharma is being acquired at $14.50 per share and a contingent value right and is trading at $14.69. The contingent value right consists of 2 milestones that pay out $1 and $1.50 on certain conditions.
Why Shares of Amryt Pharma Jumped This Week
fool.com
2023-01-12 15:32:07A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares.
Acquisition Of Amryt Pharma: How To Profit From Orphan Drugs Developers
seekingalpha.com
2023-01-12 13:52:52Amryt Pharma plc will be acquired by Chiesi Farmaceutici S.p.A. Amryt Pharma is valued at $1.25 billion plus $225 million upon achievement of certain pipeline development milestones.
New Strong Sell Stocks for December 7th
zacks.com
2022-12-07 08:17:06ABST, AMYT and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on December 7, 2022.
New Strong Sell Stocks for November 17th
zacks.com
2022-11-17 09:02:17BRFS, AOS and AMYT have been added to the Zacks Rank #5 (Strong Sell) List on November 17, 2022.
New Strong Sell Stocks for November 16th
zacks.com
2022-11-16 09:02:12EGO, BRFS and AMYT have been added to the Zacks Rank #5 (Strong Sell) List on November 16, 2022.
New Strong Sell Stocks for November 10th
zacks.com
2022-11-10 09:02:20AMYT, CHRD and BKI have been added to the Zacks Rank #5 (Strong Sell) List on November 10, 2022.
Amryt Pharma PLC (AMYT) Q3 2022 Earnings Call Transcript
seekingalpha.com
2022-11-05 22:34:22Amryt Pharma PLC (NASDAQ:AMYT ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - CEO & Director Rory Nealon - CFO, COO & Company Secretary Sheila Frame - President, Americas Tracy Cunningham - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Edward Nash - Canaccord Genuity Catherine Novack - Jones Research Brian White - Shore Capital Group Douglas Tsao - H.C. Wainwright & Co. Operator Good morning, and welcome to the Amryt Pharma Q3 2022 Results Call and Webcast.
Amryt to Report Q3 2022 Results on November 3, 2022
globenewswire.com
2022-10-19 07:00:00A mryt to Report Q 3 202 2 Results on November 3 , 2022
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022
globenewswire.com
2022-09-07 07:00:00Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022
Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-08-06 04:40:10Amryt Pharma plc (NASDAQ:AMYT ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - Chief Executive Officer Rory Nealon - Chief Financial Officer and Chief Operating Officer Jordi Casals - President of EMEA Region Sheila Frame - President of Americas Tracy Cunningham - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Catherine Novack - Jones Research Douglas Tsao - H.C. Wainwright & Co. Max Herrmann - Stifel, Nicolaus & Company, Inc. Brian White - Shore Capital Stockbrokers Ltd.
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2022-08-04 12:02:19Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amryt to Report Q2 2022 Results on August 4, 2022
globenewswire.com
2022-07-21 07:00:00DUBLIN, Ireland, and Boston MA, July 21 , 202 2 , Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the second quarter 2022 will be released on Thursday , August 4 , 202 2 at 0700 E T/1200 BST.
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
zacks.com
2022-07-14 13:10:29The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.
Amryt Pharma PLC Sponsored ADR (AMYT) Surges 7.5%: Is This an Indication of Further Gains?
zacks.com
2022-06-24 10:09:33Amryt Pharma PLC Sponsored ADR (AMYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.